This IND clearance is a routine procedural milestone for a pre-revenue biotech. The stock may see a modest positive reaction from the de-risking of the IND, but the Phase 1 study is early-stage and enrollment has not yet begun. Monitor for initial patient dosing and any early safety data, which are the next catalysts.
Price Chart
Executive Summary
Prelude Therapeutics announced FDA clearance to begin a Phase 1 study of PRT13722, an oral KAT6A selective degrader for HR+/HER2- breast cancer. The IND clearance is a procedural milestone allowing the company to initiate first-in-human dosing, with enrollment expected in Q4 2026. For an early-stage biotech with a $423M market cap, this is a modest regulatory step forward, not a value-inflection event, as the asset remains years from pivotal data or commercialization.
Key Facts
- FDA cleared Prelude's IND for PRT13722, an oral KAT6A selective degrader
- Phase 1 study is first-in-human, open-label, multicenter, evaluating safety, PK/PD, and antitumor activity as monotherapy and in combination
- Enrollment expected to begin in Q4 2026
- PRT13722 targets HR+/HER2- breast cancer, including patients with actionable mutations
- Prelude believes selective KAT6A degradation may improve therapeutic window vs dual KAT6A/B inhibitors
Financial Impact
No financial terms disclosed; IND clearance is a regulatory step with no immediate revenue or cost impact beyond standard Phase 1 trial expenses
Risk Factors
- Phase 1 trials have high failure rates; safety or efficacy signals may not support advancement
- Selective KAT6A degradation is a novel mechanism with unproven clinical benefit vs dual inhibitors
- Prelude is pre-revenue and will require additional financing to fund development, creating dilution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3359362 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | Institutional Cluster | $4.85 $4.31 | ▼ −11.13% | ▼ −10.41% | $3.81 (−21.44%) |
Sep 10, 2026 6w ago | 8-K | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.81 (−18.42%) |
Sep 10, 2026 6w ago | Press Release | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.81 (−18.42%) |
Aug 11, 2026 11w ago | 8-K | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.81 (−28.38%) |
Aug 11, 2026 11w ago | Press Release | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.81 (−28.38%) |
May 12, 2026 24w ago | 8-K | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.81 (−17.89%) |
May 12, 2026 24w ago | Press Release | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.81 (−17.89%) |
Apr 28, 2026 25w ago | 3 | $4.27 $4.27 | · 0.00% | ▼ −1.02% | $3.81 (−10.77%) |
Apr 21, 2026 27w ago | Insider Cluster | $4.27 $5.23 | ▲ +22.48% | ▲ +21.46% | $3.81 (−10.77%) |
Apr 20, 2026 27w ago | 8-K | $4.51 $4.62 | ▲ +2.44% | ▲ +3.09% | $3.81 (−15.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers